Pharma Stocks

TRAWS PHARMA ($TRAW) Releases Q4 2025 Earnings

By: Quiver EarningsTracker Posted: an hour ago / April 15, 2026 8:30 p.m. UTC TRAWS PHARMA ($TRAW) posted quarterly earnings…

Read More »

Luye Pharma (02186.HK) LY03017 Completes First Patient Enrollment in China Phase II Clinical Trial AASTOCKS Financial News

You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…

Read More »

CSPC PHARMA (01093.HK) SYS6051 Drug Approved for Clinical Trials in China AASTOCKS Financial News

You expressly agree that the use of this app/website is at your sole risk. AASTOCKS.com Limited, HKEx Information Services Limited,…

Read More »

Is its wide-moat pharma strategy strong enough to unlock new upsid

Sanofi’s durable competitive advantages in vaccines and rare diseases position it for steady growth amid industry shifts. For investors in…

Read More »

Is efzofitimod’s pulmonary sarcoidosis data strong enough to u

With efzofitimod advancing in late-stage trials for pulmonary sarcoidosis, you need to know if aTyr Pharma’s immunology focus can deliver…

Read More »

A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia

Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in…

Read More »

Is its diversified pharma model strong enough to unlock new

You’re looking at a healthcare giant with deep roots in pharmaceuticals, medical devices, and consumer health—does this structure position it…

Read More »

Bristol Myers Squibb: Value Stock Analysis for Dividend Investors in 2026 – News and Statistics

Apr 14, 2026 The pharmaceutical industry is often viewed as a high-growth yet risky sector, but some companies within it…

Read More »

Is U.S. market growth strong enough to unloc

Sun Pharma’s expanding U.S. specialty drug portfolio positions it for higher-margin growth amid supply chain shifts. For investors in the…

Read More »

How Investors Are Reacting To Roche Holding (SWX:ROG) CE Mark For Elecsys NfL MS Blood Test

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for…

Read More »